Accelerating biotechnology to transform Europe’s emergency response capability, this is the ambition driving SPEEDCELL, a four-year project co-funded by the European Union and led by HIPRA. By developing faster, more efficient cell-line–based production technologies, SPEEDCELL is helping pave the way for a future in which essential vaccines and biological products can be made available in record time. 

At the heart of this effort is a clear goal: enabling Europe to deliver critical medical measures within 100 days of detecting a new health threat. This vision, known as the EU’s 100-Day Mission, emerged after the COVID-19 pandemic and aims to ensure a stronger, more agile and better-prepared Europe. 

Laura Ferrer Soler, R&D Director of HIPRA Human Health Division, emphasizes how SPEEDCELL is designed to meet this challenge. She explains that the project accelerates key development steps and strengthens HIPRA’s production capabilities, showcasing the organisation’s scientific and technological robustness.  

By being fully executed by HIPRA group companies, SPEEDCELL leverages integrated expertise to build a faster, more resilient development and manufacturing platform for biotechnological products. Through innovation, process optimisation and advanced cell-line technologies, SPEEDCELL is expanding Europe’s capacity to react swiftly when new health emergencies arise. 

The project not only improves the speed at which biological solutions can be produced but also reinforces Europe’s strategic autonomy and preparedness for the future.